Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER). The optimal dose remains debated, with the standard 10 mg dose often causing significant daytime sedation. Recent evidence suggests that lower doses (2.5 mg and 5 mg) may offer comparable efficacy with improved tolerability. However, no head-to-head randomized controlled trials (RCTs) directly compare all three doses.

NCT Number	NCT07403370
Lead Sponsor	Shandong Cancer Hospital and Institute
Conditions	Solid Tumours, Olanzapine, Nausea and Vomiting
Enrollment	2,000 participants
Start Date	2026-01-18
Primary Completion	2026-02-15 (estimated)
Study Completion	2026-03-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-19